ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2012

Conditions
Psoriasis
Interventions
DRUG

ACT-128800

ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

DRUG

Placebo

ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Trial Locations (67)

1011

Clinical Investigative Site 3101, Lausanne

1085

Clinical Investigative Site 2002, Budapest

1130

Clinical Investigative Site 1007, Vienna

1200

Clinical Investigative Site 1103, Brussels

1431

Clinical Investigative Site 1202, Sofia

1606

Clinical Investigative Site 1201, Sofia

Clinical Investigative Site 1203, Sofia

2400

Clinical Investigative Site 1502, Copenhagen

2650

Clinical Investigative Site 1102, Edegem

3100

Clinical Investigative Site 1004, Sankt Pölten

3529

Clinical Investigative Site 2006, Miskolc

4000

Clinical Investigative Site 1101, Liège

Clinical Investigative Site 1504, Roskilde

4002

Clinical Investigative Site 1204, Plovdiv

4012

Clinical Investigative Site 2001, Debrecen

5800

Clinical Investigative Site 1205, Pleven

6000

Clinical Investigative Site 1206, Stara Zagora

6720

Clinical Investigative Site 2003, Szeged

6807

Clinical Investigative Site 1006, Feldkirch

7624

Clinical Investigative Site 2005, Pécs

8036

Clinical Investigative Site 1002, Graz

8091

Clinical Investigative Site 3103, Zurich

8200

Clinical Investigative Site 2004, Veszprém

10034

Clinical Investigative Site 1401, Prague

16132

Clinical Investigative Site 2317, Genova

17176

Clinical Investigative Site 3001, Stockholm

24128

Clinical Investigative Site 2303, Bergamo

28041

Clinical Investigative Site 2902, Madrid

28922

Clinical Investigative Site 2904, Madrid

36038

Clinical Investigative Site 3512, Poltava

40138

Clinical Investigative Site 2307, Bologna

42055

Clinical Investigative Site 1702, Saint-Etienne

50005

Clinical Investigative Site 1402, Hradec Králové

53203

Clinical Investigative Site 1406, Pardubice

56126

Clinical Investigative Site 2310, Pisa

60020

Clinical Investigative Site 2315, Ancona

67100

Clinical Investigative Site 2309, L’Aquila

69063

Clinical Investigative Site 3514, Zaporizhia

69310

Clinical Investigative Site 1705, Pierre-Bénite

74101

Clinical Investigative Site 1405, Nový Jičín

75475

Clinical Investigative Site 1707, Paris

75877

Clinical Investigative Site 1710, Paris

86021

Clinical Investigative Site 1704, Bordeaux

Clinical Investigative Site 1703, Poitiers

90185

Clinical Investigative Site 3006, Umeå

91775

Clinical Investigative Site 2708, Trnava

97517

Clinical Investigative Site 2704, Banská Bystrica

300074

Clinical Investigative Site 2602, Timișoara

350020

Clinical Investigative Site 3410, Krasnodar

400006

Clinical Investigative Site 2604, Cluj-Napoca

410167

Clinical Investigative Site 2606, Oradea

540342

Clinical Investigative Site 2605, Târgu Mureş

550245

Clinical Investigative Site 2607, Sibiu

700368

Clinical Investigative Site 2603, Iași

A-1090

Clinical Investigative Site 1001, Vienna

06202

Clinical Investigative Site 1701, Nice

00133

Clinical Investigative Site 2304, Roma

00168

Clinical Investigative Site 2316, Rome

Unknown

Clinical Investigative Site 3801, Vilnius

Clinical Investigative Site 2907, Las Palmas de Gran Canaria

011461

Clinical Investigative Site 2608, Bucharest

020125

Clinical Investigative Site 2601, Bucharest

04015

Clinical Investigative Site 2705, Kosice-Saca

04166

Clinical Investigative Site 2701, Košice

08025

Clinical Investigative Site 2901, Barcelona

DD1 9SY

Clinical Investigative Site 3306, Dundee

E11 1NR

Clinical Investigative Site 3304, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY